£200,000 Capital Investment Broadens Molecular Profiles’ Analytical Capability
Molecular Profiles, a leading pharmaceutical development service provider, announced the installation of its most recent capital investment, a new state-of-the-art Confocal Raman Microscope.
The Raman microscope located within the companies on-site spectroscopy and imaging suites, adds to the multimillion pound investment in Molecular Profiles mpanalytics service sector.
Molecular Profiles are routinely called upon, by global pharmaceutical clients, to provide materials characterisation for preformulation activities and assist in the understanding and development of early and late stage formulations across all dosage forms.
Dr. Shen Luk, Chief Scientific Officer, announced, “Raman microscopy is an important emerging technique to aid pharmaceutical development and life sciences in general. The acquisition of a second Raman microscope from Witec underlines the growing importance of this technique and our commitment to provide the best capability for our clients.”
Molecular Profiles’ formulation development services for early phase clinical trials also benefits from the unique offerings of the companies on-site materials characterisation expertise. Nikin Patel, CEO commented, “Continued investment in our analytical sector helps assure our clients of reduced development risk, knowing that we can provide end to end R&D under one roof and bring new formulations rapidly to clinical trials.”
Molecular Profiles is a privately owned pharmaceutical development company based in Nottingham UK. The company provides, early phase formulation development services, materials characterisation, advanced product analysis and consulting services to pharmaceutical and life science companies world-wide.